The Roadmap for Care: Treatment Strategies for JAK1 Deficiency
At a Glance
Partial JAK1 deficiency usually requires prolonged combinations of antibiotics chosen for the specific mycobacterial infection. Interferon-gamma or a stem cell transplant may be considered only in selected severe cases, with specialist monitoring and strict BCG vaccine precautions.
Because partial JAK1 deficiency is exceptionally rare, there is no “one-size-fits-all” treatment plan [1]. Instead, your medical team—which should include specialists in pediatric infectious diseases and immunology—will build a strategy tailored specifically to your child’s unique genetic profile and the specific bacteria they are fighting [2].
The Foundation: Prolonged Antimycobacterial Therapy
The first line of defense is a combination of powerful antibiotics designed to kill mycobacteria. Unlike a standard 10-day course of antibiotics for an ear infection, treating MSMD requires a marathon, not a sprint [3].
- Multi-Drug Regimens: Doctors use multiple drugs simultaneously. These are not a standard protocol; instead, clinicians determine the combination based on the species, susceptibility, and site of disease. Examples may include rifampin, ethambutol, and isoniazid, sometimes supplemented with agents like clarithromycin or levofloxacin depending on the specific “bug” [2][3].
- Extended Duration: Treatment often lasts for many months, but duration is highly individualized based on clinical response, culture conversion, and relapse risk [3][4]. Never stop or alter therapy based on a calendar estimate.
- Susceptibility-Guided: It is vital that the laboratory identifies the exact species of bacteria (such as the BCG strain or a specific environmental mycobacterium) to ensure the drugs being used are effective [5][6].
The Challenge of Recombinant IFN-gamma
In some other forms of MSMD, doctors use injections of recombinant Interferon-gamma (IFN-γ) to boost the immune system. However, this may not work for your child [7].
- The Transmission Problem: IFN-γ is the signal, and it binds the receptor on the outside. In your child’s case, the body makes the signal, but the JAK1 “transmitter” inside cannot pass it along [1]. Adding more signal (IFN-γ) often does not help if the internal transmission is the problem [7].
- The Exception: If functional testing shows that your child’s cells still have some “residual” function, a doctor might consider a trial of IFN-γ [8][9]. This requires specialist interpretation, defined endpoints, and careful monitoring.
Hematopoietic Stem Cell Transplant (HSCT)
For children with severe or life-threatening MSMD that does not respond well to antibiotics, a stem cell transplant (bone marrow transplant) is sometimes considered [10].
While potentially curative for certain severe MSMDs, HSCT is an exceptional, highly individualized, and potentially experimental option for partial JAK1 deficiency, as replacing the blood-forming cells may not correct a defect in nonhematopoietic tissues [11].
HSCT is a high-risk procedure with serious considerations:
- Graft-Versus-Host Disease (GVHD): The new immune cells may attack the child’s body [11][12].
- Infection Risk: The process of “clearing out” the old immune system to make room for the new one leaves the child very vulnerable to other infections [11].
- Uncertainty: Because JAK1 deficiency is so new, there is very little data on how these specific patients fare with transplants [13].
Managing Long-Term Risks
Long-term antibiotic use is necessary but requires careful monitoring for side effects:
- Organ Toxicity: Regular blood tests are needed to ensure the liver remains healthy [3][14]. The plan may also include vision monitoring for ethambutol, or hearing/kidney monitoring for other drugs. Create a medication-monitoring checklist with your clinic.
- Drug Resistance: Using antibiotics for a long time can sometimes lead to bacteria becoming “smarter” and resistant to the drugs [2][14].
Important Safety for the Family
If your child has MSMD, there are critical rules for vaccines and the safety of the whole family:
- No BCG Vaccine: Your diagnosed child must not receive the live BCG vaccine, as it can cause a widespread, dangerous infection [15]. Other live vaccines require an individualized decision based on immune function and specialist guidance.
- Screen Siblings First: If you have other children or are planning to have more, they should not receive the BCG vaccine until they have been genetically tested for the known familial variant [16][17]. Even siblings who seem perfectly healthy could carry the genetic trait [18][6]. You should also seek genetic counseling for recurrence-risk counseling.
Common questions in this guide
What is the usual treatment for partial JAK1 deficiency?
Could interferon-gamma help a child with JAK1 deficiency?
When might a stem cell transplant be considered for JAK1 deficiency?
What monitoring is needed during long-term treatment?
Can a child with partial JAK1 deficiency receive the BCG vaccine?
Should siblings be tested before receiving the BCG vaccine?
Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial JAK1 deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteria.
Daza-Cajigal V, Albuquerque AS, Young DF, et al.
Frontiers in immunology 2022; (13()):888427 doi:10.3389/fimmu.2022.888427.
PMID: 36159783 - 2
Effective anti-mycobacterial treatment for BCG disease in patients with Mendelian Susceptibility to Mycobacterial Disease (MSMD): a case series.
Mahdaviani SA, Fallahi M, Jamee M, et al.
Annals of clinical microbiology and antimicrobials 2022; (21(1)):8 doi:10.1186/s12941-022-00500-y.
PMID: 35232430 - 3
Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children.
Alsuhaibani M, Felimban G, Shoukri M, et al.
International journal of pediatrics & adolescent medicine 2019; (6(2)):47-50 doi:10.1016/j.ijpam.2019.01.003.
PMID: 31388545 - 4
Case report: IL12RB1 deficiency in an infant with disseminated Bacille Calmette-Guérin disease.
Ma X, Chen J, Cheng J, Wang J
Frontiers in immunology 2025; (16()):1728612 doi:10.3389/fimmu.2025.1728612.
PMID: 41668770 - 5
Pediatric Mycobacterium bovis Infection: Clinical Spectrum, BCG-Related Disease, Primary Immunodeficiency, and a Comprehensive Review of the Literature.
Mete Atasever N, Dede E, Köksalan K, et al.
Vaccines 2026; (14(10)) doi:10.3390/vaccines14100867.
PMID: 42931396 - 6
Persistent Ascites Revealing Mendelian Susceptibility to Mycobacterial Disease Due to IL-12Rβ1 Deficiency: A Case Report and Review of the Literature.
Dolikhani M, Shakibamaram G, Rashtian P, et al.
Case reports in immunology 2026; (2026()):3587297 doi:10.1155/crii/3587297.
PMID: 42643649 - 7
Mendelian susceptibility to mycobacterial diseases: State of the puzzle.
Errami A, Bousfiha AA
Qatar medical journal 2023; (2023(2)):25 doi:10.5339/qmj.2023.sqac.25.
PMID: 38025345 - 8
Characteristics of Mycobacterial, COVID-19, and Talaromyces Marneffei Infections in Patients with IL12RB1 and IFNGR1 Mutations in Western China.
Zhang W, Zhang Z, Liu C, et al.
Journal of clinical immunology 2026; (46(1)).
PMID: 41957131 - 9
Novel STAT1 Variants in Japanese Patients with Isolated Mendelian Susceptibility to Mycobacterial Diseases.
Ono R, Tsumura M, Shima S, et al.
Journal of clinical immunology 2023; (43(2)):466-478 doi:10.1007/s10875-022-01396-1.
PMID: 36336768 - 10
Mendelian susceptibility to mycobacterial disease: IFN-γ-driven immunity collapse underlies heterogeneous infections.
Qian M, Zhou J, Zhou Q, et al.
Frontiers in immunology 2026; (17()):1781297 doi:10.3389/fimmu.2026.1781297.
PMID: 42183200 - 11
Tailored conditioning for hematopoietic stem cell transplantation in children with Mendelian susceptibility to mycobacterial disease: A tale of two pathways for IFN-γ and IL-12 defects.
Ganesan K, Balwani M, Seshadri N, et al.
Journal of human immunity 2026; (2(5)):e20250264 doi:10.70962/jhi.20250264.
PMID: 42516312 - 12
Outcome of Hematopoietic Stem Cell Transplantation in patients with Mendelian Susceptibility to Mycobacterial Diseases.
Radwan N, Nademi Z, Lum SH, et al.
Journal of clinical immunology 2021; (41(8)):1774-1780 doi:10.1007/s10875-021-01116-1.
PMID: 34387798 - 13
Clinical Relevance of Gain- and Loss-of-Function Germline Mutations in STAT1: A Systematic Review.
Zhang W, Chen X, Gao G, et al.
Frontiers in immunology 2021; (12()):654406 doi:10.3389/fimmu.2021.654406.
PMID: 33777053 - 14
Disseminated Bacillus Calmette-Guérin and Susceptibility to Mycobacterial Infections-Implications on Bacillus Calmette-Guérin Vaccinations.
Lee PP
Annals of the Academy of Medicine, Singapore 2015; (44(8)):297-301.
PMID: 26477962 - 15
Mendelian Susceptibility to Mycobacterial Disease (MSMD): Clinical, Immunological, and Genetic Features of 22 Patients from 15 Moroccan Kindreds.
Errami A, Baghdadi JE, Ailal F, et al.
Journal of clinical immunology 2023; (43(4)):728-740 doi:10.1007/s10875-022-01419-x.
PMID: 36630059 - 16
Adverse reactions to Mycobacterium bovis bacille Calmette-Guérin vaccination against tuberculosis in Iranian children.
Mahmoudi S, Khaheshi S, Pourakbari B, et al.
Clinical and experimental vaccine research 2015; (4(2)):195-9 doi:10.7774/cevr.2015.4.2.195.
PMID: 26273579 - 17
Disseminated BCGosis in immunocompromised infants: a five-case series in the context of a national BCG vaccination policy change.
Alhusaini W, Sanyour G, Kutbi R, et al.
BMC pediatrics 2026; (26(1)).
PMID: 42337472 - 18
Mendelian susceptibility to mycobacterial disease in tuberculosis-hyperendemic South Africa.
Cornelissen HM, Glanzmann B, Van Coller A, et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2021; (111(10)):998-1005 doi:10.7196/SAMJ.2021.v111i10.15341.
PMID: 34949297
This page is for informational purposes only and does not constitute medical advice. Your child's infectious disease and immunology specialists should guide antibiotic, vaccine, IFN-γ, and transplant decisions.